Usaa Fund Holdings Usaa Nasdaq-100 Index Fund
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
AUTOMOTIVE AFTERMARKET OUTLOOK and REFLECTIONS from OUR Nd 42 ANNUAL SYMPOSIUM October 29 – October 30, 2018
GAMCO Investors, Inc. November 21, 2018 One Corporate Center Rye, NY 10580-1435 Tel (914) 921-5150 www.gabelli.com AUTOMOTIVE AFTERMARKET OUTLOOK AND REFLECTIONS FROM OUR nd 42 ANNUAL SYMPOSIUM October 29 – October 30, 2018 PRESENTING COMPANIES 10/31/2018 10/31/2017 11/1/2016 Company Exchange Ticker Price (a) Price (a) Price (a) AutoZone, Inc NYSE AZO $ 733.47 $ 589.50 $ 734.45 Boyd Group Income Fund (b) TSX BYD.UN 120.31 96.10 81.17 BYD Company Ltd (c) SHE 002594 46.79 62.79 55.57 Cooper Tire & Rubber Co. NYSE CTB 30.89 32.80 35.10 Dana, Inc. " DAN 15.47 30.49 15.00 Donaldson Company, Inc " DCI 51.28 47.21 35.46 Gentex Corporation NASDAQ GNTX 21.05 19.04 15.96 Genuine Parts Co. NYSE GPC 97.92 88.23 86.43 Lear Corporation " LEA 132.90 175.59 121.30 Monro, Inc. NASDAQ MNRO 74.40 49.35 53.32 Motorcar Parts of America, Inc " MPAA 21.18 28.91 26.19 Navistar International Corp NYSE NAV 33.49 42.31 23.01 O'Reilly Automotive, Inc NASDAQ ORLY 320.75 210.95 264.24 Penske Automotive Group NYSE PAG 44.02 46.62 42.83 Rush Enterprises, Inc. NASDAQ RUSHB 35.95 47.59 24.77 Standard Motor Products, Inc NYSE SMP 53.90 43.67 46.88 Superior Industries International, Inc. " SUP 9.83 15.55 22.95 Tenneco, Inc. " TEN 34.43 58.11 56.06 US Auto Parts Network, Inc. NASDAQ PRTS 1.19 2.56 2.27 Veoneer, Inc. -
Amgen and Incyte – the Biotechnology Acquisition
Amgen and Incyte – the biotechnology acquisition Ana Carolina Coelho Student number: 152416013 Dissertation written under the supervision of António Luís Borges de Assunção Dissertation submitted in partial fulfilment of requirements for the MSc in Finance, at the Universidade Católica Portuguesa, May 2018 Abstract The main goal of this dissertation is to study the hypothesis of an acquisition in the biotechnology industry, between Amgen (acquirer) and Incyte (target). Amgen is a U.S.-based biotechnology company currently facing a decrease in sales, mainly due to an increase in the market share of generic drugs and the rise of biosimilar products. To offset the poor performance, it is looking for an acquisition in its industry, for which Incyte could be a suitable target. Incyte belongs to the U.S.-biotechnology industry, and although it has a shy presence in the market with only two released drugs, its revenues are expected to increase significantly in the near future. The combination of these companies would allow knowledge transfer about research and development process of new drugs, a stronger position in Europe, and a higher investment power to apply in R&D. The combined company would be able to decrease the number of employees due to duplication of jobs and decrease the cost of sales, as the power over suppliers increases. The potential synergies are valued at $28,522.8 million, of which $16,739.2 million are more likely to be realized. The combined firm, after the introduction of synergies, is expected to generate the same or even higher returns than the sum of the stand- alone businesses and higher growth rates, fulfilling Amgen’s need of growth. -
City of Vadnais Heights Accounts Payable Printed: 08/28/2018 15:50 User:Leslee Checks by Date - Detail by Check Date Detail
City of Vadnais Heights Accounts Payable Printed: 08/28/2018 15:50 User:leslee Checks by Date - Detail By Check Date Detail Check Amount Check No: 76626 Check Date: 08/21/2018 Vendor: ZuehlkeJ Jason J Zuehlke Bean bag tournament vendor HD 08/21/2018 200.00 Check Total: 200.00 Date Totals: 200.00 Check No: 76627 Check Date: 09/04/2018 Vendor: AspenMil Aspen Mills 221384 Uniforms - P Yang 08/23/2018 517.95 Check Total: 517.95 Check No: 76628 Check Date: 09/04/2018 Vendor: AutoData ADP, INC 520015802 PP ending 8/17/18 08/28/2018 320.17 Check Total: 320.17 Check No: 76629 Check Date: 09/04/2018 Vendor: BrowersJ John & Caitlyn Browers RefundFina Refund on overpmt of final UB 9975-0 08/23/2018 45.85 Check Total: 45.85 Check No: 76630 Check Date: 09/04/2018 Vendor: CentraPe Central Pension Fund PP ending 8/17/18 08/23/2018 200.00 Check Total: 200.00 Check No: 76631 Check Date: 09/04/2018 Vendor: CenturyL Century Link August 08/23/2018 58.36 August 08/23/2018 45.10 Check Total: 103.46 Check No: 76632 Check Date: 09/04/2018 Vendor: Cintas Cintas 4009096039 8/28/18 08/28/2018 112.38 4008882028 8/21/18 08/28/2018 110.99 Check Total: 223.37 Check No: 76633 Check Date: 09/04/2018 Vendor: CityRose City of Roseville 0224909 Aug PR1 chgs 08/28/2018 157.58 0224862 Aug Metro INET 08/28/2018 6,273.00 0224909 Aug phone support 08/28/2018 627.80 Check Total: 7,058.38 Check No: 76634 Check Date: 09/04/2018 Vendor: Comcast Comcast 8/20-9/19 8/30-9/19 cable services 08/23/2018 6.28 Check Total: 6.28 Check No: 76635 Check Date: 09/04/2018 Vendor: ComoLube Como -
Align Technology, Inc. 2006 Annual Report
our path is clear... Align Technology, Inc. Inc. Technology, Align 2006 Annual Report2006 Annual 881 Martin Ave. Santa Clara, CA 95050 408.470.1000 www.aligntech.com Align Technology, Inc. 002CS-13275 2006 Annual Report in every sense officers and directors EXECUTIVE TEAM Len Hedge Joseph S. Lacob Thomas M. Prescott Vice President, Operations Partner Kleiner Perkins Caufield & Byers President and Michael Henry Chief Executive Officer Vice President, C. Raymond Larkin, Jr. Eldon M. Bullington Information Technology Chairman of the Board Vice President, Finance and Chief Information Officer Align Technology, Inc. and Chief Financial Officer Gil Laks George Morrow Hossein Arjomand Vice President, International Executive Vice President Amgen, Inc. Vice President, Research Darrell Zoromski and Development Vice President, Global Marketing Thomas M. Prescott Sonia Clark and Chief Marketing Officer President and Chief Executive Officer Vice President, Human Resources BOARD OF DIRECTORS Align Technology, Inc. Dan S. Ellis H. Kent Bowen Vice President, Bruce Rauner Professor of Greg J. Santora North American Sales Business Administration Former Chief Financial Officer Harvard University Graduate Shopping.com Roger E. George School of Business Administration Vice President, Legal and Warren S. Thaler Corporate Affairs, General Counsel David E. Collins President and Corporate Secretary Former Vice Chairman Gund Investment Corporation Johnson & Johnson shareholder information CORPORATE INVESTOR RELATIONS TRANSFER AgENT HEADQUARTERS For additional -
FEA Newsletter October 2011
October Issue - 11th Anniversary Issue PreSys™ R3 Release BETA CAE Systems S.A. FE Modeling Tool release ANSA v13.2.0 ESI engineer David Prono transatlantic boat race The Stealth LLNL M. King (left) and physicist W. Moss B-2 Spirit compression test helmet pad TABLE OF CONTENTS 2. Table of Contents 4. FEA Information Inc. Announcements 5. Participant & Industry Announcements 6. Participants 7. BETA CAE Systems S.A. announces the release of ANSA v13.2.0 11. Making A Difference Guenter & Margareta Mueller 13. LLNL researchers find way to mitigate traumatic brain injury 16. ESI sponsors in-house engineer David Prono for a transatlantic boat race 18. ETA - PreSys™ R3 Release FE Modeling Tool Now Offers ‘Part Groups’ Function 20. Toyota Collaborative Safety Research Center 23. LSTC SID-IIs-D FAST - Finite Element Model 27. Website Showcase The Snelson Atom 28. New Technology - “Where You At?” 29. SGI - Benchmarks- Top Crunch.org 35. Aerospace - The Stealth 2 36. Reference Library - Available Books 38. Solutions - PrePost Processing - Model Editing 39. Solutions - Software 40. Cloud Services – SGI 42. Cloud Services – Gridcore 43. Global Training Courses 50. FEA - CAE Consulting/Consultants 53. Software Distributors 57. Industry News - MSC.Software 59. Industry News – SGI 60. Industry News - CRAY 3 FEA Information Inc. Announcements Welcome to our 11th Anniversary Issue. A special thanks to a few of our first participant’s that supported, and continue to support FEA Information Inc.: Abe Keisoglou and Cathie Walton, (ETA) US, Brian Walker, Oasys, UK Christian Tanasecu, SGI, Guenter and Margareta Mueller, CADFEM Germany, Sam Saltiel, BETA CAE Systems SA, Greece Companies - JSOL - LSTC With this issue we will be adding new directions, opening participation, and have brought on additional staff. -
ANSYS Contact Technology Guide
ANSYS Contact Technology Guide ANSYS Release 9.0 002114 November 2004 ANSYS, Inc. is a UL registered ISO 9001: 2000 Company. ANSYS Contact Technology Guide ANSYS Release 9.0 ANSYS, Inc. Southpointe 275 Technology Drive Canonsburg, PA 15317 [email protected] http://www.ansys.com (T) 724-746-3304 (F) 724-514-9494 Copyright and Trademark Information Copyright © 2004 SAS IP, Inc. All rights reserved. Unauthorized use, distribution or duplication is prohibited. ANSYS, DesignSpace, CFX, DesignModeler, DesignXplorer, ANSYS Workbench environment, AI*Environment, CADOE and any and all ANSYS, Inc. product names referenced on any media, manual or the like, are registered trademarks or trademarks of subsidiaries of ANSYS, Inc. located in the United States or other countries. ICEM CFD is a trademark licensed by ANSYS, Inc. All other trademarks and registered trademarks are property of their respective owners. ANSYS, Inc. is a UL registered ISO 9001: 2000 Company. ANSYS Inc. products may contain U.S. Patent No. 6,055,541. Microsoft, Windows, Windows 2000 and Windows XP are registered trademarks of Microsoft Corporation. Inventor and Mechanical Desktop are registered trademarks of Autodesk, Inc. SolidWorks is a registered trademark of SolidWorks Corporation. Pro/ENGINEER is a registered trademark of Parametric Technology Corporation. Unigraphics, Solid Edge and Parasolid are registered trademarks of Electronic Data Systems Corporation (EDS). ACIS and ACIS Geometric Modeler are registered trademarks of Spatial Technology, Inc. FLEXlm License Manager is a trademark of Macrovision Corporation. This ANSYS, Inc. software product and program documentation is ANSYS Confidential Information and are furnished by ANSYS, Inc. under an ANSYS software license agreement that contains provisions concerning non-disclosure, copying, length and nature of use, warranties, disclaimers and remedies, and other provisions. -
Download All Holdings (PDF)
AMG River Road Large Cap Value Select Fund - Portfolio Holdings as of August 31, 2021 Ticker Name Sector Asset Class Country Currency Par/Shares Price ($) Market Value ($) % of Fund BRK/B Berkshire Hathaway Inc, Class B Financials Stock US USD 12,533 285.77 $3,581,555 8.58% FISV Fiserv Inc Information Technology Stock US USD 28,343 117.79 $3,338,522 7.99% KKR KKR & Co Inc, Class A Financials Stock US USD 49,455 64.29 $3,179,462 7.61% LBRDK Liberty Broadband Corp, Class C Communication Services Stock US USD 13,067 191.32 $2,499,978 5.99% LSXMK Liberty Media Corp-Liberty SiriusXM, Class C Communication Services Stock US USD 49,095 49.35 $2,422,838 5.80% CMCSA Comcast Corp, Class A Communication Services Stock US USD 38,255 60.68 $2,321,313 5.56% KDP Keurig Dr Pepper Inc Consumer Staples Stock US USD 62,389 35.67 $2,225,416 5.33% LKQ LKQ Corp Consumer Discretionary Stock US USD 38,918 52.69 $2,050,589 4.91% NSRGY Nestle SA ADR Consumer Staples Stock CH USD 15,712 126.29 $1,984,268 4.75% PGR Progressive Corp Financials Stock US USD 20,171 96.34 $1,943,274 4.65% DLTR Dollar Tree Inc Consumer Discretionary Stock US USD 19,858 90.54 $1,797,943 4.30% AEP American Electric Power Co Inc Utilities Stock US USD 19,922 89.57 $1,784,414 4.27% GOOG Alphabet Inc, Class C Communication Services Stock US USD 605 2909.24 $1,760,090 4.21% TMUS T-Mobile US Inc Communication Services Stock US USD 11,822 137.02 $1,619,850 3.88% MCK McKesson Corp Health Care Stock US USD 7,889 204.14 $1,610,460 3.86% CVS CVS Health Corp Health Care Stock US USD 18,504 86.39 -
Inozyme Pharma Expands Medical Leadership Team
Inozyme Pharma Expands Medical Leadership Team Strengthens Inozyme’s Ability to Advance Lead Candidate, INZ-701, into Clinical Trials Boston, Mass., Nov. 14, 2019 – Inozyme Pharma Inc., a biotechnology company developing novel medicines to treat rare and life-threatening mineralization disorders, today announced the addition of three industry veterans to its leadership team: • Pedro Huertas M.D., Ph.D., as Chief Medical Officer, • Gus Khursigara Ph.D., as Vice President of Medical Affairs and Clinical Operations, and • Catherine Nester, as Vice President of Physician and Patient Strategies. The executives will be instrumental in advancing Inozyme’s lead drug candidate, INZ-701, into clinical trials in 2020 for the treatment of patients with ENPP1 deficiency. INZ-701 is the first therapy that addresses the pathology of ENPP1 deficiency, including diseases such as generalized arterial calcification of infancy (GACI) type 1 and autosomal recessive hypophosphatemic rickets type 2 (ARHR2), both of which are rare and life-threatening manifestations of this enzyme deficiency. Inozyme Pharma received orphan drug designation for INZ-701 in the US and EU in 2018. “We are pleased and excited to welcome Pedro, Gus and Catherine to the Inozyme team,” said Axel Bolte, co-founder and chief executive officer of Inozyme. “Their expertise in orphan drug development – spanning medical affairs, regulatory affairs and clinical development – will strengthen and accelerate our ability to bring potentially life-saving medicines to people who urgently need effective treatments.” Dr. Huertas, a veteran of the pharmaceutical industry, has extensive experience in research and development and medical and regulatory affairs, especially regarding rare disorders and enzyme replacement therapies. -
Polen Capital and the Focus Growth Some of Our Faster-Growing Technology Strategy
Polen Focus Growth Portfolio Manager Commentary – September 2020 Summary • During the third quarter of 2020, the Polen Focus • Gambling-like behavior in the market should give Growth Composite Portfolio (the “Portfolio”) anyone pause in our view, and we are remaining returned 10.15% gross of fees versus 13.22% for the conservative in our estimates of future earnings Russell 1000 Growth Index (the Index”) and 8.93% for growth and the prices we are willing to pay. the S&P 500. Year to date, the Portfolio has returned 22.25% gross of fees versus 24.33% for the Russell • In the third quarter, we initiated new positions in 1000 Growth and 5.57% for the S&P 500. UnitedHealth Group and Intuitive Surgical and eliminated our position in ADP. We also trimmed our • The U.S. election is just around the corner, and while positions in MSCI, ServiceNow, PayPal, Align the outcome is uncertain, we believe the operating Technology, and Microsoft. environment for our businesses over the long run is unlikely to change materially. • Valuations in the U.S. equity market continued to climb in the third quarter. While we feel comfortable with the businesses we own and their valuations, we have seen some ebullient behavior in certain companies that gives us pause. Seeks Growth & Capital Preservation (Performance (%) as of 9-30-2020) 1 Yr 3 Yr 5 Yr Inception 40 30 20 10 0 Qtr YTD 1 Yr 3 Yr 5 Yr Inception Polen Focus Growth (Gross) 10.15 22.25 35.17 24.83 21.04 15.42 Polen Focus Growth (Net) 10.01 21.81 34.53 24.24 20.46 14.43 Russell 1000 Growth TR 13.22 24.33 37.54 21.68 20.11 11.24 S&P 500 TR 8.93 5.57 15.15 12.28 14.15 10.53 The performance data quoted represents past performance and does not guarantee future results. -
Victory Fund Holdings Victory Rs Mid Cap Growth
VICTORY FUND HOLDINGS As of June 30, 2021 VICTORY RS MID CAP GROWTH FUND MATURITY TRADED MARKET TRADED MARKET SECURITY DESCRIPTION DATE VALUE (BASE) VALUE (BASE) % ADVANCED DRAINAGE SYSTEMS INC 3,267,457.10 0.71% ALIGN TECHNOLOGY INC 6,788,210.00 1.48% AMERISOURCEBERGEN CORP. 4,443,356.90 0.97% APELLIS PHARMACEUTICALS INC 3,165,688.00 0.69% ARISTA NETWORKS INC 3,079,635.00 0.67% AVANTOR INC 4,718,923.90 1.03% AXON ENTERPRISE INC 6,244,576.00 1.37% BILL.COM HOLDINGS INC 4,132,540.80 0.90% BOSTON BEER COMPANY INC-CLASS A 3,521,760.00 0.77% BUILDERS FIRSTSOURCE INC 3,443,941.80 0.75% BURLINGTON STORES INC 5,383,672.80 1.18% CAESARS ENTERTAINMENT INC 4,181,125.00 0.91% CARMAX INC. 2,479,680.00 0.54% CARRIER GLOBAL CORP 5,655,096.00 1.24% CENTENE CORP. 3,567,079.23 0.78% CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 8,030,963.20 1.76% CHART INDUSTRIES INC 3,985,756.80 0.87% CHEWY INC-CLASS A 5,215,106.46 1.14% CHIPOTLE MEXICAN GRILL, INC. 9,922,176.00 2.17% COSTAR GROUP INC 6,517,934.00 1.43% CROWDSTRIKE HOLDINGS INC-A 6,242,540.40 1.36% DARDEN RESTAURANTS, INC. 2,988,415.30 0.65% DEXCOM, INC. 5,435,710.00 1.19% DOCUSIGN INC 8,635,917.30 1.89% DOLBY LABORATORIES INC 4,895,824.90 1.07% DROPBOX INC 3,032,818.60 0.66% ENPHASE ENERGY INC 4,557,696.60 1.00% ENTEGRIS INC 7,171,610.40 1.57% FAIR ISAAC CORP. -
Annual Report November 30, 2019 Ticker Symbol: YCGEX
YCG ENHANCED FUND a series of the YCG Funds Annual Report November 30, 2019 Ticker Symbol: YCGEX Beginning on January 1, 2021, as permitted by regulations adopted by the SEC, paper copies of the Fund’s shareholder reports will no longer be sent by mail, unless you specifically request paper copies of the reports from the Fund (defined herein) or from your financial intermediary, such as a broker-dealer or bank. Instead, the reports will be made available on the Fund’s website ( www.ycgfunds.com ), and you will be notified by mail each time a report is posted and provided with a website link to access the report. If you already elected to receive shareholder reports electronically, you will not be affected by this change and you need not take any action. You may elect to receive shareholder reports and other communications from the Fund by contacting your financial intermediary (such as a broker-dealer or bank) or, if you are a direct investor, by calling 855-444-YCGF (855-444-9243) or by sending an e-mail request to [email protected] . You may elect to receive all future reports in paper free of charge. If you invest through a financial intermediary, you can contact your financial intermediary to request that you continue to receive paper copies of your shareholder reports. If you invest directly with the Fund, you can call 855-444-YCGF (855-444-9243) or send an e-mail request to [email protected] to let the Fund know you wish to continue receiving paper copies of your shareholder reports. -
2016 Proxy Statement
28MAR201619370983 DOLLAR TREE, INC. 500 Volvo Parkway Chesapeake, Virginia 23320 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS to be held on Thursday, June 16, 2016 To Our Shareholders: We will hold the annual meeting of shareholders of Dollar Tree, Inc. at The Founders Inn, 5641 Indian River Road, Virginia Beach, Virginia 23464 on Thursday, June 16, 2016 at 8:00 a.m. local time, for the following purposes: • To elect eleven director nominees to the Company’s Board of Directors as identified in the attached proxy statement, each to serve as a director for a one-year term; • To approve, by a non-binding advisory vote, the compensation of the Company’s named executive officers; • To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year 2016; • To approve the material terms of performance goals under the Omnibus Incentive Plan; and • To act upon any other business that may properly come before the meeting. Shareholders of record at the close of business on April 15, 2016 will receive notice of and be allowed to vote at the meeting. Your vote is important to us. We encourage you to read the attached proxy statement and then vote by Internet, by phone or sign, date and return your proxy card in the enclosed envelope at your earliest convenience. Sending in your proxy card will not prevent you from voting your shares at the meeting, if you desire to do so. By Order of the Board of Directors 28MAR201619314328 WILLIAM A. OLD, JR. Corporate Secretary Chesapeake, Virginia May 18, 2016 IMPORTANT NOTICE ABOUT THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 16, 2016 The Company’s proxy statement and annual report to shareholders for the fiscal year ended January 30, 2016 are available at http://www.dollartreeinfo.com/investors/ financial/annuals/ TABLE OF CONTENTS Page INFORMATION ABOUT THE ANNUAL MEETING AND VOTING .....................